218 related articles for article (PubMed ID: 23919889)
1. Olanzapine depot formulation in rat: a step forward in modelling antipsychotic-induced metabolic adverse effects.
Skrede S; Martins L; Berge RK; Steen VM; López M; Fernø J
Int J Neuropsychopharmacol; 2014 Jan; 17(1):91-104. PubMed ID: 23919889
[TBL] [Abstract][Full Text] [Related]
2. Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression.
Han M; Deng C; Burne TH; Newell KA; Huang XF
Psychoneuroendocrinology; 2008 Jun; 33(5):569-80. PubMed ID: 18358632
[TBL] [Abstract][Full Text] [Related]
3. Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation.
Fernø J; Varela L; Skrede S; Vázquez MJ; Nogueiras R; Diéguez C; Vidal-Puig A; Steen VM; López M
PLoS One; 2011; 6(6):e20571. PubMed ID: 21695181
[TBL] [Abstract][Full Text] [Related]
4. Olanzapine depot exposure in male rats: Dose-dependent lipogenic effects without concomitant weight gain.
Fernø J; Ersland KM; Duus IH; González-García I; Fossan KO; Berge RK; Steen VM; Skrede S
Eur Neuropsychopharmacol; 2015 Jun; 25(6):923-32. PubMed ID: 25823694
[TBL] [Abstract][Full Text] [Related]
5. A parametric analysis of olanzapine-induced weight gain in female rats.
Cooper GD; Pickavance LC; Wilding JP; Halford JC; Goudie AJ
Psychopharmacology (Berl); 2005 Aug; 181(1):80-9. PubMed ID: 15778884
[TBL] [Abstract][Full Text] [Related]
6. Olanzapine-activated AMPK signaling in the dorsal vagal complex is attenuated by histamine H1 receptor agonist in female rats.
He M; Zhang Q; Deng C; Wang H; Huang XF
Endocrinology; 2014 Dec; 155(12):4895-904. PubMed ID: 25264935
[TBL] [Abstract][Full Text] [Related]
7. Metabolic side effects induced by olanzapine treatment are neutralized by CB1 receptor antagonist compounds co-administration in female rats.
Lazzari P; Serra V; Marcello S; Pira M; Mastinu A
Eur Neuropsychopharmacol; 2017 Jul; 27(7):667-678. PubMed ID: 28377074
[TBL] [Abstract][Full Text] [Related]
8. Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration.
Minet-Ringuet J; Even PC; Goubern M; Tomé D; de Beaurepaire R
Appetite; 2006 May; 46(3):254-62. PubMed ID: 16551485
[TBL] [Abstract][Full Text] [Related]
9. A role for hypothalamic AMP-activated protein kinase in the mediation of hyperphagia and weight gain induced by chronic treatment with olanzapine in female rats.
Sejima E; Yamauchi A; Nishioku T; Koga M; Nakagama K; Dohgu S; Futagami K; Kataoka Y
Cell Mol Neurobiol; 2011 Oct; 31(7):985-9. PubMed ID: 21681559
[TBL] [Abstract][Full Text] [Related]
10. Olanzapine-depot administration induces time-dependent changes in adipose tissue endocrine function in rats.
Horska K; Ruda-Kucerova J; Babinska Z; Karpisek M; Demlova R; Opatrilova R; Suchy P; Kotolova H
Psychoneuroendocrinology; 2016 Nov; 73():177-185. PubMed ID: 27504985
[TBL] [Abstract][Full Text] [Related]
11. Betahistine ameliorates olanzapine-induced weight gain through modulation of histaminergic, NPY and AMPK pathways.
Lian J; Huang XF; Pai N; Deng C
Psychoneuroendocrinology; 2014 Oct; 48():77-86. PubMed ID: 24992721
[TBL] [Abstract][Full Text] [Related]
12. Lipid-lowering effects of tetradecylthioacetic acid in antipsychotic-exposed, female rats: challenges with long-term treatment.
Skrede S; Fernø J; Bjørndal B; Brede WR; Bohov P; Berge RK; Steen VM
PLoS One; 2012; 7(11):e50853. PubMed ID: 23226405
[TBL] [Abstract][Full Text] [Related]
13. Hypothalamic histamine H1 receptor-AMPK signaling time-dependently mediates olanzapine-induced hyperphagia and weight gain in female rats.
He M; Zhang Q; Deng C; Wang H; Lian J; Huang XF
Psychoneuroendocrinology; 2014 Apr; 42():153-64. PubMed ID: 24636512
[TBL] [Abstract][Full Text] [Related]
14. Two models for weight gain and hyperphagia as side effects of atypical antipsychotics in male rats: validation with olanzapine and ziprasidone.
Shobo M; Yamada H; Mihara T; Kondo Y; Irie M; Harada K; Ni K; Matsuoka N; Kayama Y
Behav Brain Res; 2011 Jan; 216(2):561-8. PubMed ID: 20816897
[TBL] [Abstract][Full Text] [Related]
15. Lack of Ovarian Secretions Reverts the Anabolic Action of Olanzapine in Female Rats.
Skrede S; González-García I; Martins L; Berge RK; Nogueiras R; Tena-Sempere M; Mellgren G; Steen VM; López M; Fernø J
Int J Neuropsychopharmacol; 2017 Dec; 20(12):1005-1012. PubMed ID: 29020342
[TBL] [Abstract][Full Text] [Related]
16. One-Year Treatment with Olanzapine Depot in Female Rats: Metabolic Effects.
Ersland KM; Myrmel LS; Fjære E; Berge RK; Madsen L; Steen VM; Skrede S
Int J Neuropsychopharmacol; 2019 May; 22(5):358-369. PubMed ID: 30854556
[TBL] [Abstract][Full Text] [Related]
17. Antipsychotic-induced metabolic effects in the female rat: Direct comparison between long-acting injections of risperidone and olanzapine.
Ersland KM; Skrede S; Røst TH; Berge RK; Steen VM
J Psychopharmacol; 2015 Dec; 29(12):1280-9. PubMed ID: 26378122
[TBL] [Abstract][Full Text] [Related]
18. Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution.
van der Zwaal EM; Luijendijk MC; Adan RA; la Fleur SE
Eur J Pharmacol; 2008 May; 585(1):130-6. PubMed ID: 18378227
[TBL] [Abstract][Full Text] [Related]
19. Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: implications for animal models of antipsychotic-induced weight gain.
Cooper GD; Harrold JA; Halford JC; Goudie AJ
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):428-36. PubMed ID: 17933447
[TBL] [Abstract][Full Text] [Related]
20. Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain.
Weston-Green K; Huang XF; Deng C
PLoS One; 2012; 7(3):e33548. PubMed ID: 22438946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
